



JIM GIBBONS
Governor

STATE OF NEVADA
DEPARTMENT OF HUMAN RESOURCES
DIVISION OF HEALTH CARE FINANCING AND POLICY
NEVADA MEDICAID

MICHAEL J. WILLDEN
Director

CHARLES DUARTE
Administrator

NOTICE OF OPEN PUBLIC MEETING

The Division of Health Care Financing and Policy ("DHCFP"), Pharmacy and Therapeutics Committee, will conduct a public meeting on **June 21, 2007**, beginning at **1:00 p.m.** at the following location:

**The Orleans Hotel
4500 W. Tropicana Ave.
Las Vegas, NV 89103**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Pat Manning at: 775-684-3678 or email pmanning@dhcfp.state.nv.us in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.

Public comment may be limited to 3 minutes per person or per company/product at the discretion of the Chairperson.

AGENDA

- I. Call to Order and Roll Call
- II. *Review and Approval of March 22, 2007, Meeting Minutes
- III. Public Comment

ANNUAL REVIEW – DRUG CLASSES WITH PROPOSED CHANGES

- IV. Antidepressants: Novel
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- V. Anti-Migraine Agents: Triptans
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

1100 E. William Street, Suite 102, Carson City, Nevada 89701
(775) 684-3600

- VI. Cardiovascular: Antihyperlipidemics: Statins and Statin Combinations
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VII. Cardiovascular: Beta Blockers
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- VIII. Central Nervous System: ADHD/Stimulants/Non-Stimulants
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- IX. Ophthalmic Antihistamines
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- X. Respiratory: Beta-Adrenergic Agents, Long-Acting Inhaled
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL
- XI. Respiratory: Glucocorticoids, Inhalers
 - A. Public Comment
 - B. Drug Class Review Presentation – First Health Services
 - C. *Committee Discussion and Action
 - 1. Approve Clinical/Therapeutic Equivalency of Agents in Class
 - 2. Identify Exclusions/Exceptions for Certain Patient Groups
 - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
 - E. * Committee Discussion and Approval of Drugs for Inclusion in the PDL

- XII. Annual Review - Drug Classes without Proposed Changes
- A. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy without Changes
1. Analgesics: Long-Acting Narcotics
 2. Antibiotics: Cephalosporins Second Generation
 3. Antibiotics: Cephalosporins Third Generation
 4. Antibiotics: Macrolides
 5. Antibiotics: Quinolones Second Generation
 6. Antibiotics: Quinolones Third Generation
 7. Antidepressants: SSRIs
 8. Antimetics: Oral, 5-HT₃s
 9. Antifungals: Onychomycosis Agents
 10. Antihistamines: Second Generation
 11. Bone Ossification Agents: Bisphosphonates
 12. Cardiovascular: ACE Inhibitors & Diuretic Combinations
 13. Cardiovascular: Angiotensin II Receptor Blockers & Diuretic Combinations
 14. Cardiovascular: Antihyperlipidemics: Cholesterol Absorption Inhibitors
 15. Cardiovascular: Antihyperlipidemics: Niacin Derivatives
 16. Cardiovascular: Antihyperlipidemics: Triglyceride Lowering Agents
 17. Cardiovascular: Calcium Channel Blockers & ACEI Combinations
 18. Central Nervous System: Hypnotics
 19. Electrolyte Depleters
 20. Gastrointestinal Agents: H₂RAs
 21. Gastrointestinal Agents: PPIs
 22. Hepatitis C Agents
 23. Herpetic Antiviral Agents
 24. Immunomodulators: Injectable
 25. Immunomodulators: Topical
 26. Leukotriene Modifiers
 27. Multiple Sclerosis Agents
 28. Nasal Calcitonins
 29. Ophthalmic Glaucoma Agents
 30. Ophthalmic Quinolones
 31. Otic Fluoroquinolones
 32. Respiratory: Anticholinergic Agents, Inhaled
 33. Respiratory: Beta-Adrenergic Agents, Short-Acting Inhaled
 34. Respiratory: Glucocorticoids, Nasal
 35. Urinary Antispasmodics
- B. * Committee Discussion and Approval of Drug Classes without changes for the PDL
- XIII. Report by FHSC on Brand Name Preferred Drugs Converted to Generic Status and Line Extensions
- XIV. Review of Next Meeting Location, Date, and Time
- XV. Public Comment
- XVI. *Adjournment

*** Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site (dhcfp.state.nv.us).

Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral

County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.

If requested in writing, a copy of the action items will be mailed to you or they may be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1100 E. William Street, Suite 102, Carson City, NV 89701.

All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.

Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.